EDTA chelation
Detox · Polyamine chelator
Tier F
High-risk evidence profile
Bottom line
Read Off Label grades EDTA chelation as F (1.8/10) based on very weak evidence, low benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 1.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
TACT (Trial to Assess Chelation Therapy) 2013 showed marginal CV benefit that generated ongoing controversy; TACT2 (2023) in diabetics failed to replicate.
Studied, labeled, or reported-use context: 50 mg/kg/day IV for lead (max 2 g); 1-3 g/L oral suppository protocols have no validated evidence — Rx (calcium disodium EDTA); OTC 'chelation' suppositories unregulated/unvalidated; not individualized guidance.
What the evidence says
TACT (Trial to Assess Chelation Therapy) 2013 showed marginal CV benefit that generated ongoing controversy; TACT2 (2023) in diabetics failed to replicate. Oral/suppository EDTA products sold for 'plaque removal' have essentially no evidence. Legitimate role is acute inorganic lead toxicity.
Mechanism
Ethylenediaminetetraacetic acid; binds divalent metals (Ca²⁺, Pb²⁺, Fe³⁺, etc.) via tetradentate chelation; IV/IM forms used for lead toxicity; oral has poor absorption
Studied, labeled, or reported dose & route
50 mg/kg/day IV for lead (max 2 g); 1-3 g/L oral suppository protocols have no validated evidence
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about EDTA chelation's effects?
- Read Off Label rates the evidence for EDTA chelation as Very Weak and the benefit magnitude as low, producing an overall grade of F (1.8/10). TACT (Trial to Assess Chelation Therapy) 2013 showed marginal CV benefit that generated ongoing controversy; TACT2 (2023) in diabetics failed to replicate.
- What safety findings are reported for EDTA chelation?
- EDTA chelation has a med-high risk profile in the database. Med-High (hypocalcemia — potentially fatal if infused too fast; renal toxicity; mineral depletion) Legal status: Rx (calcium disodium EDTA); OTC 'chelation' suppositories unregulated/unvalidated.
- What does the low Safety score for EDTA chelation represent?
- The Safety score is 1.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for EDTA chelation?
- 50 mg/kg/day IV for lead (max 2 g); 1-3 g/L oral suppository protocols have no validated evidence This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does EDTA chelation work?
- Ethylenediaminetetraacetic acid; binds divalent metals (Ca²⁺, Pb²⁺, Fe³⁺, etc.) via tetradentate chelation; IV/IM forms used for lead toxicity; oral has poor absorption
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.